November 29, 2021
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating a new side effect risk for the multiple sclerosis (MS) treatment Imusera/Gilenya (fingolimod), a move likely to trigger label changes in the near future. According to the agency’s risk communication update...read more